Chảy máu tiêu hóa do thuốc gây ra

Rollhauser C, Fleischer DE (2004) Nonvariceal upper gastrointestinal bleeding. Endoscopy 36:52–58 Ohmann C, Imhof M, Ruppert C et al (2005) Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol 40:914–920 Crooks CJ, West J, Card TR (2013) Comorbidities affect risk of nonvariceal upper gastro-intestinal bleeding. Baillieres Clin Gastroenterol 144:1384–1393 Lanas Á et al (2015) Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 13:906–912 Götz M, Anders M, Biecker E et al (2017) S2k-Leitlinie Gastrointestinale Blutung. Z Gastroenterol 55:883–936 Salvo F, Fourrier-Reglat A, Bazin F et al (2011) Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 89(6):855–866 Huang JQ, Sridhar S, Hunt RH (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 539:14–22 Silverstein FE, Faich G, Goldstein JL (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 284:1247–1255 Emery P, Zeidler H, Kvien TK et al (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: a randomised double-blind comparison. Lancet 354:2106–2111 Niculescu L, Huang J, Mallen S (2009) Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin 25:729–740 Baraf HSB, Fuentealba C, Greenwald M et al (2007) Gastrointestinal side effects of etoricoxib in patiens with osteoarthritis: results oft he Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 34:408–420 Goldstein JL, Eisen GM, Lewis B et al (2007) Small bowel mucosal injury is reduced in healthy subjects with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 25:1211–1222 Laine L, Smith R, Min K et al (2006) Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 24:751–767 Chan FK, Hung LC, Suen BY et al (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104–2110 Chan FK, Wong VW, Suen BY et al (2007) Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369:1621–1626 Fischbach W, Malfertheiner P, Lynen P et al (2016) S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 54:327–363 ACTIVE Investigators, Conolly SJ, Pogue J, Hart RG et al (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360(20):2066–2078 Lanas A, Fuentes J, Benito R et al (2002) Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 16:779–786 CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339 Serebruany VL, Malinin AI, Ferguson JJ et al (2008) Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comparing 129 314 patients. Fundam Clin Pharmacol 22:315–321 Wiviott SD, Braunwald E, McCabe CH et al (2007) Triton-TIMI-38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–2015 Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151 Hart RG, Benavente O, McBride R, Pearce LA (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492–501 Conolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817 Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992 Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891 Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151 Holster L, Valkhoff VE, Kuipers EJ, Tjwa ETTL (2013) New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 145:105–112 Ruff CT, Giugiano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962 Li A, Garcia DA, Lyman GH, Carrier M (2018) Direct oral anticoagulant (DOAK) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res 173:158–163. https://doi.org/10.1016/j.thromres.2018.02.144 Chan FK, Lanas A, Scheiman J et al (2010) Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376:173–179 Hooper L, Brown TJ, Elliott R et al (2004) The effectiveness of five strategies fort he prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329:948 Denzer U, Beilenhoff U, Eickhoff A et al (2015) S2k-Leitlinie Qualitätsanforderungen in der gastrointestinalen Endoskopie, AWMF Register Nr. 021-022. Z Gastroenterol 53:E1–E227 Sung JJ, Lau JY, Ching JY et al (2010) Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 152:1–9 Sengupta N, Feuerstein JD, Patwardhan VR et al (2015) The risks of thromboembolism versus gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: A prospective study. Am J Gastroenterol 110:328–335